Affinity Asset Advisors LLC Has $45.52 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Affinity Asset Advisors LLC increased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,161,237 shares of the biopharmaceutical company's stock after purchasing an additional 17,216 shares during the period. Xenon Pharmaceuticals makes up approximately 6.1% of Affinity Asset Advisors LLC's portfolio, making the stock its largest position. Affinity Asset Advisors LLC owned about 1.52% of Xenon Pharmaceuticals worth $45,520,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in XENE. JPMorgan Chase & Co. boosted its stake in Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after buying an additional 905,129 shares during the last quarter. FMR LLC increased its position in shares of Xenon Pharmaceuticals by 8.8% in the 4th quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company's stock worth $294,991,000 after purchasing an additional 607,606 shares during the last quarter. Jennison Associates LLC raised its stake in Xenon Pharmaceuticals by 39.0% during the fourth quarter. Jennison Associates LLC now owns 801,553 shares of the biopharmaceutical company's stock worth $31,421,000 after acquiring an additional 224,892 shares during the period. Walleye Capital LLC lifted its position in Xenon Pharmaceuticals by 111.5% in the 4th quarter. Walleye Capital LLC now owns 221,982 shares of the biopharmaceutical company's stock valued at $8,702,000 after purchasing an additional 117,022 shares during the last quarter. Finally, TimesSquare Capital Management LLC grew its stake in shares of Xenon Pharmaceuticals by 9.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 848,850 shares of the biopharmaceutical company's stock worth $33,275,000 after purchasing an additional 70,557 shares in the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction on Friday, January 24th. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the sale, the chief executive officer now owns 31,302 shares of the company's stock, valued at approximately $1,258,340.40. This trade represents a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.52% of the company's stock.

Xenon Pharmaceuticals Stock Up 4.0 %

XENE stock traded up $1.36 during midday trading on Friday, hitting $35.14. The company's stock had a trading volume of 825,775 shares, compared to its average volume of 437,281. Xenon Pharmaceuticals Inc. has a 1 year low of $26.74 and a 1 year high of $46.00. The stock's 50-day moving average price is $35.02 and its 200 day moving average price is $38.79. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of -12.46 and a beta of 1.21.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.05. As a group, equities analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on XENE. The Goldman Sachs Group decreased their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a report on Thursday. StockNews.com lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Finally, Royal Bank of Canada reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $56.78.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.